Journal of Clinical Epidemiology
Volume 57, Issue 12 , Pages 1237-1243, December 2004

Blinding decreased recruitment in a prevention trial of postmenopausal hormone therapy

  • Elina Hemminki

      Affiliations

    • Health and Social Services, National Research and Development Center for Welfare and Health (STAKES), P.O. Box 220, 00531 Helsinki, Finland
    • Corresponding Author InformationCorresponding author. Tel. +358-9-3967-2307; fax: 358-9-3967-2227.
  • ,
  • Sirpa-Liisa Hovi

      Affiliations

    • Health and Social Services, National Research and Development Center for Welfare and Health (STAKES), P.O. Box 220, 00531 Helsinki, Finland
    • School of Public Health, University of Tampere, Tampere, Finland
  • ,
  • Piret Veerus

      Affiliations

    • School of Public Health, University of Tampere, Tampere, Finland
    • National Institute for Health Development (TAI), Department of Epidemiology and Biostatistics, Tallinn, Estonia
    • Estonian Center for Excellence in Behavioral and Health Sciences, Tallinn, Estonia
  • ,
  • Tiina Sevón

      Affiliations

    • Health and Social Services, National Research and Development Center for Welfare and Health (STAKES), P.O. Box 220, 00531 Helsinki, Finland
  • ,
  • Risto Tuimala

      Affiliations

    • Tampere University Hospital, Department of Obstetrics and Gynecology, Tampere, Finland
  • ,
  • Mati Rahu

      Affiliations

    • National Institute for Health Development (TAI), Department of Epidemiology and Biostatistics, Tallinn, Estonia
    • Estonian Center for Excellence in Behavioral and Health Sciences, Tallinn, Estonia
  • ,
  • Matti Hakama

      Affiliations

    • School of Public Health, University of Tampere, Tampere, Finland

Accepted 20 April 2004.

Abstract 

Purpose

To compare the effect of blind design (active drug and placebo) and nonblind design (active drug and no treatment) on recruitment.

Setting

A primary prevention trial with postmenopausal hormone therapy in Estonia.

Methods

Women who were eligible and willing to participate on the basis of the questionnaire survey were randomized into blind and nonblind groups. Recruitment rates are based on record keeping, and reasons for participating were requested in the first-year follow-up.

Results

The recruitment was 30% higher in the nonblind group: of the 4,295 women invited, 37% (95% confidence interval CI=35–39%) in the blind group and 48% (95% CI=46–49%) in the nonblind group were recruited. In both groups, once randomized, most of the losses were women who did not attend the first clinical examination: 49% (blind; 95% CI=47–51%) and 40% (nonblind; 95% CI=38–42%). The rest were found ineligible or lost their interest during clinical examinations. The reasons for joining the trial were relatively similar in the two groups.

Conclusions

Blinding decreased women's interest in joining a long-term preventive trial. Women's reasons for joining the trial were not influenced by blinding.

Keywords: Prevention trial, Recruitment, @@@Blinding, Hormone therapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0895-4356(04)00173-8

doi:10.1016/j.jclinepi.2004.04.009

Journal of Clinical Epidemiology
Volume 57, Issue 12 , Pages 1237-1243, December 2004